Symbols

ZLAB

Zai Lab·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ZLAB

Zai Lab Limited

A biotech company that develops and commercializes innovative oncology and autoimmune therapies in China and globally

Industry

Biological Technology

Established Date

03/28/2013

Listing Date

09/20/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

1,784

Fiscal Year Ends

12-31

Website

www.zailaboratory.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

899 Halei Road, Building B, Pudong, Shanghai, PRC

Business

Zai Lab Limited and its affiliates are committed to addressing the huge unmet medical needs in the fields of oncology, immunity, neuroscience and infectious diseases through the discovery, development and commercialization of innovative products.

Introduction

Zai Lab Limited is a holding company mainly engaged in biopharmaceuticals. The company is committed to addressing unmet medical needs in oncology, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The company has a portfolio of patented drug candidates from the discovery stage to the later stages of clinical programs. These include "Zele", "OPTUNE", "Qingle", "New Zele" and "Weiweijia".

Company Financials

EPS

ZLAB has released its 2025 Q4 earnings. EPS was reported at -0.05, versus the expected -0.37, beating expectations. The chart below visualizes how ZLAB has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ZLAB has released its 2025 Q4 earnings report, with revenue of 127.60M, reflecting a YoY change of 16.99%, and net profit of -50.41M, showing a YoY change of 38.29%. The Sankey diagram below clearly presents ZLAB's revenue sources and cost distribution.